Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of ranibizumab for the treatment of persistent diabetic neovascularization as assessed by super wide-field angiography (optos).

Next Previous
Trial Profile

Investigation of ranibizumab for the treatment of persistent diabetic neovascularization as assessed by super wide-field angiography (optos).

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic retinopathy
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 29 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 21 Jul 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
  • 01 Mar 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top